Structure Therapeutics Inc. (GPCR)
Insiders here have filed 9 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$215.1M
- Net margin
- —
Little or no net debt.
- Total debt
- $6.2M
- Cash
- $272.6M
- Debt / equity
- 0.00
Comfortably covers what is due within a year.
- Current assets
- $1.37B
- Current liabilities
- $66.1M
- Current ratio
- 20.75
Consumes cash and must keep raising it.
- Operating cash flow
- -$220.2M
- Free cash flow
- -$224.5M
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 72.7M
- Share growth (1y)
- 25.4%
- Cash runway
- 15 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
GPCR Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| SG&A Expense | 18.57 M | 22.87 M | 17.57 M | 14.80 M | 15.74 M |
| R&D Expense | 100.06 M | 66.51 M | 68.69 M | 58.99 M | 54.71 M |
| Operating Expenses | 118.63 M | 89.38 M | -13.74 M | 73.79 M | 70.45 M |
| Operating Income | -118.63 M | -89.38 M | 13.74 M | -73.79 M | -70.45 M |
| Pretax Income | -105.92 M | -75.78 M | 33.17 M | -65.60 M | -61.52 M |
| Tax Provision | 234.00 K | 190.00 K | 170.00 K | 108.00 K | 139.00 K |
| Net Income | -106.16 M | -75.97 M | 33.00 M | -65.71 M | -61.66 M |
| EPS (Basic) | -1.47 | -1.05 | 0.47 | -1.11 | -1.07 |
| EPS (Diluted) | -1.47 | -1.05 | 0.47 | -1.11 | -1.07 |
| Shares Outstanding | 72.65 M | 72.44 M | 70.84 M | 58.49 M | 57.57 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.